TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8732126
Drug: Shuxuening tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening tablet No. 1 (crude extract)
Study: 8732126
Drug: Shuxuening tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening tablet No. 2 (pure extract)
Study: 8732126
Drug: Shuxuening tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuening tablet No. 1 and No. 2
Study: 1748495
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 micrograms twice daily for 4 weeks
Study: 1748495
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily for 4 weeks
Study: 7140487
Drug: Chenodeoxycholic (chenic)
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic (chenic) acid, 15 mg/kg/day, administered in three divided doses at mealtimes with an unrestricted diet (Group A)
Study: 7140487
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of chenodeoxycholic (chenic) acid, 15 mg/kg/day, with a low cholesterol diet (Group B)
Study: 30228368
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic infiltration with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine
Study: 28072552
Drug: Dextenza (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextenza (sustained-release dexamethasone intracanalicular insert)
Study: 16813177
Drug: Needle-picking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-picking therapy at bilateral Shengzhi points, Dicong Shenjing points and L2 Shenjing points
Study: 16813177
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Wuzi Yanzong Pills
Study: 12635531
Drug: Remifentanil-propofol (remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil-propofol (remifentanil 0.4 microgram/kg and propofol 1 mg/kg)
Study: 12635531
Drug: Alfentanil-propofol (alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil-propofol (alfentanil 20 micrograms/kg and propofol 1 mg/kg)
Study: 10720025
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy (starting dose, 10 microg/kg x day, final dose 4 microg/kg x day)
Study: 25233155
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy
Study: 30014331
Drug: Saline instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline instillation (SI) 20-mL/kg of body weight
Study: 25635958
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the masseter muscle
Study: 25635958
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the TMJ
Study: 18368945
Drug: Nanopril (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanopril (test formulation)
Study: 9552084
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone injections (n=22)
Study: 7848350
Drug: Test patch
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test patch (Deponit 5)
Study: 7848349
Drug: Reference patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference patch
Study: 3153709
Drug: oxaprotiline (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaprotiline (75, 150, 225 mg/day for 4 weeks)
Study: 3153709
Drug: doxepin (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxepin (75, 150, 225 mg/day for 4 weeks)
Study: 23238616
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (α-LA) 600 mg intravenous injection daily for 5 days
Study: 18849890
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (general)
Study: 17081897
Drug: 5 IU/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IU/mL low-molecular-weight heparin (LMWH) in the infusion fluid
Study: 10848883
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg
Study: 10848883
Drug: DHEA 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 200 mg
Study: 30004919
Drug: More frequent
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More frequent imaging (monthly)
Study: 19996069
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with a systolic blood pressure target of <130 mm Hg, using valsartan (160 or 320 mg) plus amlodipine (5 or 10 mg)
Study: 19996069
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with a systolic blood pressure target of <140 mm Hg, using valsartan (160 or 320 mg) plus amlodipine (5 or 10 mg)
Study: 15987849
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate supplementation (CaP; 1.0 g elemental calcium)
Study: 12721265
Drug: BMS-247550 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-247550 at a dose of 6 mg/m2/d administered as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days
Study: 12721265
Drug: BMS-247550 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-247550 at a dose of 8 mg/m2/d with filgrastim support
Study: 12721265
Drug: BMS-247550 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-247550 at a dose of 6 mg/m2/d
Study: 25491299
Drug: Intravitreal autologous
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal autologous CD34+ BM cell therapy
Study: 22208833
Drug: Weekly spaced
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly spaced education e‐mails with content designed to improve teaching skills (group A)
Study: 20595285
Drug: Anti-TNF inhibitors
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF inhibitors (exact type not specified)
Study: 7770402
Drug: Calcium nadroparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium nadroparin (0.3 ml daily, 3075 anti-Xa IU)
Study: 7770402
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (0.2 ml-5000 UI if <70 kg or 0.3 ml-7500 IU if ≥70 kg, twice a day)
Study: 2182705
Drug: Rifampin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (300 mg daily for 2 weeks)
Study: 2182705
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 2 weeks)
Study: 44234
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic treatment
Study: 44234
Drug: Other drug
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drug treatment
Study: 44234
Drug: Beta-adrenoreceptor-blocking drugs
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-adrenoreceptor-blocking drugs (suggested therapy)
Study: 29672935
Drug: Hawthorn (Crataegus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hawthorn (Crataegus oxyacantha) 160 mg
Study: 27147610
Drug: IC adenosine
Normalized name: Cyclic adenosine monophosphate
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC adenosine (2-3 mg total)
Study: 27147610
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (500 μg total)
Study: 24599772
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme with leucine supplementation (10 g/day)
Study: 22465904
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/d) plus zinc (440 mg/d)
Study: 24115188
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus placebo
Study: 19293160
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg once weekly plus methotrexate (MTX)
Study: 18035427
Drug: CIPRODEX Otic
Normalized name: Ciprodex Otic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPRODEX Otic Suspension (CIP/DEX) - four drops instilled into each middle ear through tympanostomy tubes
Study: 16101608
Drug: 600 microg
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 microg oral misoprostol
Study: 16101608
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with four 0.5-mg ergometrine tablets
Study: 12808615
Drug: Octreotide in
Normalized name: octreotide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide in combination with IFN-alpha
Study: 1602956
Drug: Mannitol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (250 cc intravenous at 20% injected in 1 h)
Study: 1602956
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (intravenous perfusion glucose serum 250 cc with 1 g of vitamins C, 250 mg of vitamin B6 and 1 g of calcium gluconate injected in 1 h)
Study: 3902523
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (hCG) administered intramuscularly, initial dosage of 10,000 IU followed by 5,000 IU twice weekly up to week 12, then once weekly up to week 16
Study: 28581284
Drug: Topical mydriatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriatic
Study: 24809882
Drug: Clocortolone pivalate
Normalized name: Clocortolone Pivalate
DrugBank: Clocortolone (DB00838)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clocortolone pivalate cream 0.1% (Cloderm Cream, Promius Pharma)
Study: 24809882
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate lotion
Study: 22869562
Drug: GS-9451 60
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 60 mg once daily
Study: 22869562
Drug: GS-9451 200
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 200 mg
Study: 22869562
Drug: GS-9451 400
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 400 mg
Study: 22869562
Drug: GS-9451 200
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9451 200 mg and 400 mg
Study: 15668859
Drug: Intravenous dalbavancin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dalbavancin (1000 mg single dose followed by 500 mg one week later)
Study: 15668859
Drug: Intravenous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vancomycin (administered twice daily for 14 days)
Study: 11886001
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel 35 mg/m2, gemcitabine 800 mg/m2 and cisplatin 35 mg/m2, on days 1 and 8 every 3 weeks
Study: 11886001
Drug: Weekly docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly docetaxel, gemcitabine and cisplatin
Study: 7498206
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg
Study: 7641363
Drug: Losartan-Captopril combination
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan-Captopril combination
Study: 8061848
Drug: Spirapril 12
Normalized name: spirapril 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 12 mg once daily
Study: 9711470
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg once daily
Study: 2238185
Drug: Hydrochlorthiazide 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorthiazide 12.5 mg daily (as a supplement to spirapril)
Study: 2238185
Drug: Hydrochlorthiazide (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorthiazide (as a supplement to nitrendipine)
Study: 22444187
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline pretreatment
Study: 15450054
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of antipsychotic medications
Study: 15450054
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with antipsychotic medications
Study: 11588698
Drug: Caspofungin 50
Normalized name: caspofungin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 50 mg/day
Study: 11588698
Drug: Caspofungin 70
Normalized name: caspofungin 70 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 70 mg/day
Study: 9870832
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.5 mg/kg/day
Study: 7916274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (beta-blocker therapy)
Study: 2688346
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg IV every 6 hours for 8 days)
Study: 472340
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg 15‐methyl‐PGF2 alpha methyl ester
Study: 472340
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg 15‐methyl‐PGF2 alpha methyl ester
Study: 472340
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 15‐methyl‐PGF2 alpha methyl ester
Study: 30878222
Drug: Ivermectin (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150-200 μg/kg) and albendazole (400 mg) plus five further doses of ivermectin alone at 3-week intervals over 18 weeks
Study: 30878222
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received single oral doses of ivermectin (150-200 μg/kg) and albendazole (400 mg) without further doses of ivermectin
Study: 23338110
Drug: bupivacaine 8.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 8.0 mg + clonidine 75 µg + morphine 100 µg
Study: 23338110
Drug: bupivacaine 10
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 10 mg + clonidine 75 µg + morphine 100 µg
Study: 20625342
Drug: Hypothermia therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia therapy (32.5°C) for 24 hours, started within 8 hours of injury and rewarming at a rate of 0.5°C every 2 hours
Study: 20625342
Drug: Serum GFAP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum GFAP cutoff level of 0.6 ng/mL
Study: 18025525
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg bid voriconazole
Study: 18025525
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg qd efavirenz
Study: 14987322
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg b.d. plus dietary treatment
Study: 9270067
Drug: Acentrally active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acentrally active drug that enhances AMPA receptor‐mediated currents
Study: 30742718
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to asthma medications among mothers with asthma
Study: 24747626
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN) patches applied once a day
Study: 23285271
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ISG and ITP (ITP+ISG)
Study: 20584114
Drug: Nicardipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (10 mg diluted in 10 mL of distilled water daily, N=37)
Study: 20584114
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 mL of saline water, N=37)
Study: 17356786
Drug: Adjustable medication
Normalized name: DEPEND ADJUSTABLE,MAXIMUM SM/MED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable medication dosing
Study: 17356786
Drug: Fixed medication
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed medication dosing
Study: 15365685
Drug: Intravenous citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous citalopram (10 mg, 20 mg, 40 mg, 0.33 mg/kg)
Study: 12166339
Drug: Incadronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incadronate (10 mg intravenous infusion)
Study: 12166339
Drug: Elcatonin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elcatonin (40 IU intramuscular injections twice daily for 7 days)
Study: 7791151
Drug: Salsalate 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate 3.0 g/day (titrated to 3.55 g/day)
Study: 7791151
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg/day (titrated to 112 mg/day)
Study: 1983322
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nizatidine b.d.
Study: 2570012
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nizatidine nocte
Study: 583489
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (Digacin)
Study: 2631854
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B
Study: 2631854
Drug: Preparation C
Normalized name: other nasal preparation combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation C
Study: 583489
Drug: Preparation D
Normalized name: Digitalis preparation Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation D
Study: 30423462
Drug: Inflammatory stress
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammatory stress (Salmonella typhi vaccine)
Study: 24352094
Drug: 7% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% carbohydrate (CHO) solution (700 mL)
Study: 24352094
Drug: Placebo (0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0% CHO) (700 mL)
Study: 18246965
Drug: 9% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9% hydrogen peroxide gel (Colgate Visible White)
Study: 18246965
Drug: 20% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% carbamide peroxide gel (Opalescence)
Study: 11410799
Drug: 2 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 1)
Study: 11410799
Drug: 4 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 microg/kg G‐CSF (lenograstim) when grade 3 leukopenia or neutropenia appeared (Group 2)
Study: 11410799
Drug: 2 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 microg/kg G‐CSF (lenograstim) when grade 2 leukopenia or neutropenia appeared (Group 3)
Study: 3113331
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg) given twice a day for 2 days
Study: 30881050
Drug: Iodixanol nasal
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol nasal solution
Study: 22766389
Drug: Glucose drink
Normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose drink (25 g)
Study: 22766389
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (30 mg saccharine)
Study: 12721240
Drug: Glutamine (4
Normalized name: N5-((2E)-((2-(((2,3-bis(omega-methoxypoly(oxyethylene))propoxy)carbonyl)amino)ethoxy)imino)ethyl)glutamine (43000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (4 g orally, twice a day for 2 weeks)
Study: 12721240
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g orally, twice a day for 2 weeks)
Study: 8649495
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy and autologous bone marrow transplantation
Study: 6299503
Drug: Combined pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pelvic x-ray therapy plus a perineal proton beam boost (500 to 700 cGy dose to prostatic tumor)
Study: 6299503
Drug: Conventional pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pelvic megavoltage x-ray therapy
Study: 26860023
Drug: 20.25 mg
Normalized name: testosterone 20.25 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.25 mg of hyperbaric ropivacaine in 5% dextrose (group B)
Study: 26860023
Drug: 20.25 mg
Normalized name: testosterone 20.25 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.25 mg of plain ropivacaine (group A)
Study: 22512265
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg/day)